Bronchiectasis Clinical Trials

Find Bronchiectasis Clinical Trials Near You

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis

Status: Recruiting
Location: See all (134) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Body mass index (BMI) between 18-35 kilograms per square meters (kg/m\^2)

• Clinical history consistent with bronchiectasis (cough, chronic sputum production, and/or recurrent respiratory infections) that is confirmed on chest computed tomography (CT)

• Meet one of the two criteria:

‣ In the 12 months prior to screening, have had 2 or more documented pulmonary exacerbations that required a new antibiotic prescription by a physician or 1 pulmonary exacerbation that required hospitalization; or

⁃ In the 12 months prior to screening, have had 0 or 1 pulmonary exacerbation and a QOL-B RSS of less than (\<)50 at screening

• Current sputum producers

• Post-bronchodilator FEV1 greater than or equal to (\>=) 30 percent (%) or greater of predicted normal value

• Non-smokers or former cigarette smokers

• Males and females of childbearing and non-childbearing potential

• A female participant is eligible to participate if she is not pregnant or breastfeeding

• Is a Woman of non-childbearing potential (WONCBP) or is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of \<1

• A WOCBP must have a negative highly sensitive serum pregnancy test within 28 days before the first dose of study intervention

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol

Locations
United States
Alabama
GSK Investigational Site
RECRUITING
Mobile
Arizona
GSK Investigational Site
RECRUITING
Phoenix
California
GSK Investigational Site
RECRUITING
La Palma
GSK Investigational Site
RECRUITING
Valencia
Colorado
GSK Investigational Site
RECRUITING
Aurora
Florida
GSK Investigational Site
RECRUITING
Miami
GSK Investigational Site
RECRUITING
Miami
GSK Investigational Site
RECRUITING
Naples
GSK Investigational Site
RECRUITING
Pembroke Pines
GSK Investigational Site
RECRUITING
Plantation
GSK Investigational Site
RECRUITING
St. Petersburg
GSK Investigational Site
RECRUITING
Tamarac
GSK Investigational Site
RECRUITING
Winter Park
Indiana
GSK Investigational Site
RECRUITING
Hammond
Louisiana
GSK Investigational Site
RECRUITING
New Orleans
Maryland
GSK Investigational Site
RECRUITING
Rockville
Missouri
GSK Investigational Site
RECRUITING
St Louis
North Carolina
GSK Investigational Site
RECRUITING
Winston-salem
Nevada
GSK Investigational Site
RECRUITING
Henderson
New York
GSK Investigational Site
RECRUITING
New Hyde Park
Pennsylvania
GSK Investigational Site
RECRUITING
Dubois
South Carolina
GSK Investigational Site
RECRUITING
Anderson
GSK Investigational Site
RECRUITING
Rock Hill
GSK Investigational Site
RECRUITING
Spartanburg
GSK Investigational Site
RECRUITING
Union
Tennessee
GSK Investigational Site
RECRUITING
Franklin
GSK Investigational Site
RECRUITING
Knoxville
Texas
GSK Investigational Site
RECRUITING
Conroe
GSK Investigational Site
RECRUITING
Cypress
GSK Investigational Site
RECRUITING
Sugar Land
Virginia
GSK Investigational Site
RECRUITING
Williamsburg
Other Locations
Argentina
GSK Investigational Site
RECRUITING
Buenos Aires
GSK Investigational Site
RECRUITING
Caba
GSK Investigational Site
RECRUITING
Caba
GSK Investigational Site
RECRUITING
Rosario Provincia De Santa Fe
GSK Investigational Site
RECRUITING
San Miguel De Tucumán
GSK Investigational Site
RECRUITING
San Miguel De Tucumán
GSK Investigational Site
RECRUITING
San Miguel De Tucumán
GSK Investigational Site
RECRUITING
Santa Fe
China
GSK Investigational Site
RECRUITING
Beijing
GSK Investigational Site
RECRUITING
Chongqing
GSK Investigational Site
RECRUITING
Dongguan
GSK Investigational Site
RECRUITING
Guangzhou
GSK Investigational Site
RECRUITING
Guangzhou
GSK Investigational Site
RECRUITING
Guilin
GSK Investigational Site
RECRUITING
Hangzhou
GSK Investigational Site
RECRUITING
Huizhou
GSK Investigational Site
RECRUITING
Jiangmen
GSK Investigational Site
RECRUITING
Jiangsu
GSK Investigational Site
RECRUITING
Nanjing
GSK Investigational Site
RECRUITING
Qingyuan
GSK Investigational Site
RECRUITING
Shanghai
GSK Investigational Site
RECRUITING
Taizhou
GSK Investigational Site
RECRUITING
Weifang
GSK Investigational Site
RECRUITING
Yangzhou
GSK Investigational Site
RECRUITING
Zhanjiang
Germany
GSK Investigational Site
RECRUITING
Bendorf
GSK Investigational Site
RECRUITING
Berlin
GSK Investigational Site
RECRUITING
Frankfurt
GSK Investigational Site
RECRUITING
Frankfurt
GSK Investigational Site
RECRUITING
Geesthacht
GSK Investigational Site
RECRUITING
Hamburg
GSK Investigational Site
RECRUITING
München
Israel
GSK Investigational Site
RECRUITING
Ashdod
GSK Investigational Site
RECRUITING
Ashkelon
GSK Investigational Site
RECRUITING
Beersheba
GSK Investigational Site
RECRUITING
Haifa
GSK Investigational Site
RECRUITING
Jerusalem
GSK Investigational Site
RECRUITING
Jerusalem
GSK Investigational Site
RECRUITING
Kfar Saba
GSK Investigational Site
RECRUITING
Koranit
GSK Investigational Site
RECRUITING
Petah Tikva
GSK Investigational Site
RECRUITING
Tel Aviv
Italy
GSK Investigational Site
RECRUITING
Milan
GSK Investigational Site
RECRUITING
Naples
GSK Investigational Site
RECRUITING
Roma
Japan
GSK Investigational Site
RECRUITING
Aichi
GSK Investigational Site
RECRUITING
Aichi
GSK Investigational Site
RECRUITING
Fukuoka
GSK Investigational Site
RECRUITING
Fukuoka
GSK Investigational Site
RECRUITING
Fukuoka
GSK Investigational Site
RECRUITING
Fukuoka
GSK Investigational Site
RECRUITING
Hyōgo
GSK Investigational Site
RECRUITING
Ibaraki
GSK Investigational Site
RECRUITING
Ibaraki
GSK Investigational Site
RECRUITING
Ishikawa
GSK Investigational Site
RECRUITING
Kanagawa
GSK Investigational Site
RECRUITING
Kanagawa
GSK Investigational Site
RECRUITING
Mie
GSK Investigational Site
RECRUITING
Miyagi
GSK Investigational Site
RECRUITING
Osaka
GSK Investigational Site
RECRUITING
Tokyo
GSK Investigational Site
RECRUITING
Tokyo
GSK Investigational Site
RECRUITING
Tokyo
GSK Investigational Site
RECRUITING
Toyonaka-shi
New Zealand
GSK Investigational Site
RECRUITING
Auckland
GSK Investigational Site
RECRUITING
Kapiti
Poland
GSK Investigational Site
RECRUITING
Bialystok
GSK Investigational Site
RECRUITING
Ksawerów
GSK Investigational Site
RECRUITING
Piaseczno
GSK Investigational Site
RECRUITING
Rzeszów
GSK Investigational Site
RECRUITING
Sosnowiec
Republic of Korea
GSK Investigational Site
RECRUITING
Busan
GSK Investigational Site
RECRUITING
Incheon
GSK Investigational Site
RECRUITING
Incheon
GSK Investigational Site
RECRUITING
Jeonju
GSK Investigational Site
RECRUITING
Seoul
GSK Investigational Site
RECRUITING
Seoul
GSK Investigational Site
RECRUITING
Seoul
GSK Investigational Site
RECRUITING
Seoul
GSK Investigational Site
RECRUITING
Seoul
Spain
GSK Investigational Site
RECRUITING
Barcelona
GSK Investigational Site
RECRUITING
Barcelona
GSK Investigational Site
RECRUITING
Barcelona
GSK Investigational Site
RECRUITING
Lleida
GSK Investigational Site
RECRUITING
Madrid
GSK Investigational Site
RECRUITING
Madrid
GSK Investigational Site
RECRUITING
Madrid
GSK Investigational Site
RECRUITING
Madrid
GSK Investigational Site
RECRUITING
Merida Badajoz
GSK Investigational Site
RECRUITING
Oviedo
GSK Investigational Site
RECRUITING
Valencia
United Kingdom
GSK Investigational Site
RECRUITING
Bedford
GSK Investigational Site
RECRUITING
Bristol Avon
GSK Investigational Site
RECRUITING
Coventry
GSK Investigational Site
RECRUITING
Dagenham
GSK Investigational Site
RECRUITING
Dundee
GSK Investigational Site
RECRUITING
High Wycombe
GSK Investigational Site
RECRUITING
Little Baldon
GSK Investigational Site
RECRUITING
Liverpool
GSK Investigational Site
RECRUITING
London
GSK Investigational Site
RECRUITING
North Finchley
GSK Investigational Site
RECRUITING
Sheffield
GSK Investigational Site
RECRUITING
Tyne And Wear
Contact Information
Primary
US GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com
877-379-3718
Backup
EU GSK Clinical Trials Call Center
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
Time Frame
Start Date: 2025-10-30
Estimated Completion Date: 2027-12-10
Participants
Target number of participants: 363
Treatments
Experimental: GSK3862995B Dose Level 1
Participants will receive GSK3862995B Dose level 1.
Experimental: GSK3862995B Dose Level 2
Participants will receive GSK3862995B Dose level 2.
Placebo_comparator: Placebo
Participants will receive matching placebo.
Related Therapeutic Areas
Sponsors
Leads: GlaxoSmithKline

This content was sourced from clinicaltrials.gov